 Calliditas Therapeutics AB NASDAQ: CALT says that the opinion of the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA can be expected in Q2 of 2022. In its review of the marketing authorization application MAA for Nefecon, the CHMP has. 